IN2014DN07410A - - Google Patents

Info

Publication number
IN2014DN07410A
IN2014DN07410A IN7410DEN2014A IN2014DN07410A IN 2014DN07410 A IN2014DN07410 A IN 2014DN07410A IN 7410DEN2014 A IN7410DEN2014 A IN 7410DEN2014A IN 2014DN07410 A IN2014DN07410 A IN 2014DN07410A
Authority
IN
India
Prior art keywords
pharmaceutically acceptable
inhibitor
prodrug
relates
pharmaceutical combination
Prior art date
Application number
Other languages
English (en)
Inventor
Ralph Tiedt
Alan Buckler
Fred Harbinski
Sneha Sanghavi
Douglas Jeffery
Christopher Wilson
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IN2014DN07410A publication Critical patent/IN2014DN07410A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IN7410DEN2014 2012-04-03 2013-04-01 IN2014DN07410A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261619502P 2012-04-03 2012-04-03
PCT/US2013/034759 WO2013151913A1 (en) 2012-04-03 2013-04-01 Tyrosine kinase inhibitor combinations and their use

Publications (1)

Publication Number Publication Date
IN2014DN07410A true IN2014DN07410A (pt) 2015-04-24

Family

ID=48184451

Family Applications (1)

Application Number Title Priority Date Filing Date
IN7410DEN2014 IN2014DN07410A (pt) 2012-04-03 2013-04-01

Country Status (11)

Country Link
US (1) US20150051210A1 (pt)
EP (1) EP2833917A1 (pt)
JP (1) JP2015512447A (pt)
KR (1) KR20140146086A (pt)
CN (1) CN104244982A (pt)
AU (1) AU2013243737B2 (pt)
CA (1) CA2866321A1 (pt)
IN (1) IN2014DN07410A (pt)
MX (1) MX2014011987A (pt)
RU (1) RU2014143213A (pt)
WO (1) WO2013151913A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106458999B (zh) 2014-03-26 2019-12-03 阿斯特克斯治疗有限公司 组合
AU2015294889B2 (en) * 2014-07-31 2018-03-15 Novartis Ag Combination therapy

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
DE102005038537A1 (de) 2005-08-16 2007-02-22 Merck Patent Gmbh 1-Acyldihydropyrazolderivate
AP3433A (en) 2005-12-21 2015-10-31 Janssen Pharmaceutica Nv Triazolopyridazines as tyrosine kinase modultors
NL2000613C2 (nl) 2006-05-11 2007-11-20 Pfizer Prod Inc Triazoolpyrazinederivaten.
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
CA2667428A1 (en) 2006-10-23 2008-05-02 Sgx Pharmaceuticals, Inc. Bicyclic triazoles as protein kinase modulators
ME02372B (me) 2006-11-22 2016-06-20 Incyte Holdings Corp Imidazotriazini i imidazopiramidini kao inhibitori kinaze
JP4994044B2 (ja) * 2007-01-05 2012-08-08 シェブロンジャパン株式会社 潤滑油組成物
ES2529790T3 (es) * 2007-04-13 2015-02-25 Dana-Farber Cancer Institute, Inc. Métodos de tratamiento de cáncer resistente a agentes terapéuticos de ERBB
CN102016592A (zh) * 2008-04-29 2011-04-13 诺瓦提斯公司 监测成纤维细胞生长因子受体的激酶活性的调节的方法及所述方法的应用
CA2723617A1 (en) * 2008-05-14 2009-11-19 Amgen Inc. Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer
MX2012001838A (es) 2009-08-12 2012-02-29 Novartis Ag Compuestos de hidrazona heterociclico y sus usos para tratar cancer e inflamacion.
CN103391773A (zh) * 2010-09-27 2013-11-13 埃克塞里艾克西斯公司 用于治疗去势抵抗性前列腺癌和成骨性骨转移的met和vegf的双重抑制剂

Also Published As

Publication number Publication date
KR20140146086A (ko) 2014-12-24
AU2013243737B2 (en) 2016-06-30
EP2833917A1 (en) 2015-02-11
MX2014011987A (es) 2014-11-10
US20150051210A1 (en) 2015-02-19
RU2014143213A (ru) 2016-05-27
AU2013243737A1 (en) 2014-09-25
CA2866321A1 (en) 2013-10-10
CN104244982A (zh) 2014-12-24
JP2015512447A (ja) 2015-04-27
WO2013151913A1 (en) 2013-10-10

Similar Documents

Publication Publication Date Title
IN2015DN00598A (pt)
MX2015002040A (es) Baricitinib deuterado.
PH12014501653A1 (en) Metalloenzyme inhibitor compounds
MA39749A (fr) Dérivés de pipéridine-dione
MX2013012542A (es) Compuestos de amida y aplicacion farmaceutica para el mismo.
MX355728B (es) Inhibidores de cinasas.
HK1209277A1 (en) 1,2,4-triazine-6-carboxamide kinase inhibitors 124--6-
EP3019166A4 (en) A pharmaceutical combination for the treatment of melanoma
EP2877469A4 (en) SUBSTITUTED NAPHTHYRIDINEDIONE DERIVATIVES AS INHIBITORS OF HIV INTEGRASE
IN2014DN07996A (pt)
MX366983B (es) Derivados de 1,5-naftiridina e inhibidores de cinasa de cremallallera de leucina embrionica materna que los contienen.
MX369290B (es) Inhibidores de fbx03.
MX2015008829A (es) Momelotinib deuterado.
IN2014DN06738A (pt)
MX2014015345A (es) Inhibidores piranopiridona de tanquirasa.
MX2018003903A (es) Compuesto biciclico y uso del mismo para inhibicion de suv39h2.
UA115072C2 (uk) Похідні гідантоїну
MY165088A (en) Pharmaceutical compositions comprising alisporivir
NZ717192A (en) Anti-inflammatory tripeptides
IN2014DN07410A (pt)
EP3192511A4 (en) Pharmaceutical containing sodium-dependent phosphate transporter inhibitor
EP3472130A4 (en) DERIVATIVES OF ALIPHATIC PROLINAMIDE
PH12016500809A1 (en) Glucopyranosyl - substituted indole-urea derivatives and their use as sglt inhibitors
EP3166405A4 (en) 3'-substituted-abscisic acid derivatives
EP3069326A4 (en) Modular product vending system